The dose selection and ASPENOVA initiation de-risk the regulatory pathway for azenosertib. The DENALI topline readout by year-end 2026 is the next major catalyst, positive data could drive significant upside given the 50% PROC patient population with no approved biomarker-specific therapy. Monitor for FDA feedback on accelerated approval and any partnership or financing announcements given the cash runway into late 2027.
ZNTL drugs
ZNTL drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $4.28entry
- T+1 · 6mo ago 0.00%α +0.00% · $4.28
- T+5 · 6mo ago −17.29%α −16.13% · $3.54
- T+20 · 5mo ago −17.76%α −17.14% · $3.52
- T+60 · 3mo ago −1.40%α −5.84% · $4.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zentalis reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with no revenue. The key catalyst is the selection of the 400mg QD 5:2 dose for azenosertib monotherapy in Cyclin E1-positive PROC, advancing the DENALI Phase 2 trial toward a topline readout by year-end 2026, which could support an accelerated approval pathway. Cash of $211.8M provides runway into late 2027, funding key milestones including the ASPENOVA Phase 3 trial initiation.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.50 vs consensus -$0.52 (4.5% beat)
- Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC
- DENALI Part 2 topline readout expected by year-end 2026, potentially supporting accelerated approval
- ASPENOVA Phase 3 confirmatory trial initiated with first patient dosed
- Cash, cash equivalents and marketable securities of $211.8M as of March 31, 2026, providing runway into late 2027
- R&D expenses $28.7M in Q1 2026 vs $27.2M in Q1 2025; total operating expenses $37.9M vs $45.6M
- Net loss $35.4M in Q1 2026 vs $48.3M in Q1 2025
Financial Impact
EPS beat of $0.02 per share; cash burn of ~$34M in Q1 2026; no revenue reported
Risk Factors
- DENALI Part 2 topline data may not meet efficacy endpoints required for accelerated approval
- Competition from other WEE1 inhibitors and emerging therapies in PROC
- Cash runway only into late 2027; may require additional financing before reaching profitability
- Regulatory delays or changes in FDA accelerated approval requirements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293397 |
Track record
18 reports on ZNTL
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
- Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
- Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
- Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
- Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
- May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers